Rotator Cuff Tendinopathy
Conditions
Keywords
rotator cuff tendinopathy, ozone, steroid, ultrasonography
Brief summary
Shoulder pain accounts for approximately 16% of all musculoskeletal symptoms. Rotator cuff tendinopathy is the most common cause of shoulder pain. The aim of this study is to compare the effects of ultrasound-guided subacromial ozone (O2-O3) versus corticosteroid injection in patients with chronic rotator cuff tendinopathy.
Detailed description
Shoulder pain accounts for approximately 16% of all musculoskeletal symptoms. Rotator cuff tendinopathy is the most common cause of shoulder pain. There are limited studies comparing the efficacy of ozone and corticosteroid injections in rotator cuff tendinopathy. In this context, the aim of this study is to compare the effects of ultrasound-guided subacromial ozone (O2-O3) versus corticosteroid injection in patients with chronic rotator cuff tendinopathy.
Interventions
PROCEDUREOzone (O2-O3) injection
US-guided injections will be performed with a 5-12 MHz linear transducer (Logic e portable; GE Healthcare, China) by the same physiatrist and injections will be administered into the subacromial bursa with a posterolateral approach. 3 sessions (1 session/week) of 5 mL of ozone (O2-O3) will be injected (with a concentration of 10 μg/mL in the first session, 15 μg/mL in the second session, and 20 μg/mL in the third session).
PROCEDURECorticosteroid injection
US-guided injections will be performed with a 5-12 MHz linear transducer (Logic e portable; GE Healthcare, China) by the same physiatrist and injections will be administered into the subacromial bursa with a posterolateral approach. A mixture of 1 mL corticosteroid (betamethasone 3 mg/mL) and 1 mL lidocaine (20 mg) will be injected (1 session).
Sponsors
Gaziler Physical Medicine and Rehabilitation Education and Research Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Masking description
Outcome measures will be evaluated by an independent physiatrist, blinded for the assigned treatment.
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* aged between 18 and 70 years * pain in the shoulder region and increase in pain with overhead-throwing activity * chronic shoulder pain for more than 3 months * partial rotator cuff tear or rotator cuff tendinosis diagnosed by US or magnetic resonance imaging (MRI).
Exclusion criteria
* a full-thickness rotator cuff tear diagnosed by US or MRI * allergic reaction betamethasone or lidocaine * contraindications for ozone (O2-O3) injection, such as uncontrolled hyperthyroidism, glucose-6 phosphate dehydrogenase deficiency (G6PDD), pregnancy and platelet level \<50 103/µL * history of coagulopathy, diabetes, or hepatitis * intra-articular/subacromial injections in the last 3 months * history of shoulder infection, fracture, trauma, bony lesion, tumor or inflammatory rheumatic diseases * history of brachial plexus lesion/cervical radiculopathy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Western Ontario Rotator Cuff Index (WORC) | at baseline and change from baseline WORC at 4 weeks and 12 weeks after injections | The Western Ontario Rotator Cuff Index (WORC) is a self-administered assessment tool for rotator cuff disease. WORC has 21 questions in 5 domains consisting of work, physical symptoms, social well-being, emotional well-being, and sports and recreation. Each question is scored on a 100-mm, with higher scores demonstrating larger problems. Turkish validity of the WORC has been illustrated. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The Shoulder Pain and Disability Index (SPADI) | at baseline and change from baseline SPADI at 4 weeks and 12 weeks after injections | The Shoulder Pain and Disability Index (SPADI) is a 13 item self-assessment measurement tool to evaluate disability (8 items) and pain (5 items). The subscales of disability and pain are measured as the average of the corresponding items between 0-100, with higher scores indicating greater disability and pain. |
| Visual Analogue Scale (VAS) | at baseline and change from baseline VAS at 4 weeks and 12 weeks after injections | The severity of the patients' shoulder pain in the last week will be evaluated using the 10-point VAS (from 0 (no pain) to 10 (worst imaginable pain)) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Ultrasonographic measurements | at baseline and change from baseline ultrasonographic measurements at 4 weeks and 12 weeks after injections | supraspinatus tendon thickness, subacromial bursa thickness and acromiohumeral distance will be measured by US in both groups |
Countries
Turkey (Türkiye)
Outcome results
None listed